Biochem 2 Exam 5 study guide
1. Question: Study Guide Question: What molecules are required for transporting fatty acids from the cytoplasm into the mitochondrial matrix? Answer: Carnitine, carnitine acyltransferase I (CPT-I), carnitine-acylcarnitine translocase (CACT), and carnitine acyltransferase II (CPT-II).
2. Question: Why is the carnitine shuttle necessary for mitochondrial fatty acid oxidation? Answer: Long-chain fatty acyl-CoA cannot cross the inner mitochondrial membrane directly. Carnitine temporarily carries its fatty acyl group across the membrane, where mitochondrial fatty acyl-CoA is regenerated.
3. Question: What is the complete pathway for transporting long-chain fatty acids into the mitochondrial matrix, including enzymes, substrates, and energetic requirements? Answer: Fatty acid + CoA + ATP → fatty acyl-CoA + AMP + PPi via fatty acyl-CoA synthetase on the outer mitochondrial membrane; PPi → 2Pi via pyrophosphatase (2 ATP equivalents consumed). CPT-I transfers the acyl group from CoA to carnitine → fatty acylcarnitine + CoA. CACT imports fatty acylcarnitine into the matrix while exporting free carnitine. CPT-II transfers the acyl group from carnitine to mitochondrial CoA → fatty acyl-CoA + carnitine. Carnitine returns through CACT, and fatty acyl-CoA enters β-oxidation.
4. Question: Which fatty acids require the carnitine shuttle, and what regulates their mitochondrial entry? Answer: Long-chain fatty acids (generally ≥14 carbons) require the carnitine shuttle; short- and many medium-chain fatty acids can enter without it. Malonyl-CoA inhibits CPT-I, preventing simultaneous fatty acid synthesis and oxidation.
5. Question: Study Guide Question: What is the role of lipoprotein lipase in lipid metabolism? Answer: Lipoprotein lipase (LPL) hydrolyzes triacylglycerols in circulating chylomicrons and VLDL, releasing fatty acids for tissue uptake. It is activated by ApoC-II.
6. Question: How does lipoprotein lipase differ from hormone-sensitive lipase? Answer: Lipoprotein lipase acts extracellularly at capillary surfaces to hydrolyze circulating lipoprotein TAGs, whereas hormone-sensitive lipase acts intracellularly on stored diacylglycerols in adipocytes.
7. Question: What is the mechanism by which lipoprotein lipase distributes dietary and endogenous fatty acids to tissues? Answer: Chylomicrons (intestinal origin) or VLDL (liver origin) enter circulation → acquire ApoC-II from HDL → ApoC-II activates capillary LPL → TAG + H₂O undergoes sequential ester hydrolysis → fatty acids and glyceride products are released → muscle oxidizes fatty acids for ATP, while adipocytes re-esterify them into TAG. Chylomicrons become remnants; VLDL is progressively converted to IDL and LDL.
8. Question: Which apolipoproteins activate and inhibit lipoprotein lipase, and what happens when LPL activity is deficient? Answer: ApoC-II activates LPL; ApoC-III inhibits LPL. Reduced LPL activity impairs circulating TAG clearance, producing hypertriglyceridemia and potentially chylomicron accumulation.
9. Question: Study Guide Question: Why does phytanic acid require a special oxidation pathway? Answer: Its β-carbon contains a methyl group that prevents normal β-oxidation, so phytanic acid must first undergo peroxisomal α-oxidation.
10. Question: Why does β-methyl branching interfere with ordinary fatty acid β-oxidation? Answer: β-Oxidation requires formation of a β-ketoacyl-CoA intermediate. The methyl substituent on phytanic acid's β-carbon prevents this transformation, requiring removal of one carbon by α-oxidation.
11. Question: What is the pathway for α-oxidation of phytanic acid, including its enzymes, cofactors, and products? Answer: Phytanic acid → phytanoyl-CoA by acyl-CoA synthetase, using ATP → AMP + PPi and CoA. Phytanoyl-CoA hydroxylase hydroxylates the α-carbon, requiring O₂, Fe²⁺, and α-ketoglutarate (producing succinate and CO₂) → 2-hydroxyphytanoyl-CoA. 2-Hydroxyacyl-CoA lyase cleaves the substrate using thiamine pyrophosphate (TPP) → pristanal + formyl-CoA. Aldehyde dehydrogenase oxidizes pristanal with NAD⁺ → pristanic acid + NADH. Pristanic acid is activated to pristanoyl-CoA and undergoes peroxisomal β-oxidation, producing acetyl-CoA and propionyl-CoA.
12. Question: Which branched-chain fatty acid can undergo β-oxidation after α-oxidation, and why? Answer: Pristanic acid, the one-carbon-shorter product of phytanic acid α-oxidation. Its β-carbon is no longer blocked by a methyl substituent, allowing subsequent β-oxidation.
13. Question: Study Guide Question: How do you interpret the symbol for a polyunsaturated fatty acid like 18:2(Δ9,12)? Answer: An 18-carbon fatty acid containing two double bonds, located between carbons 9–10 and 12–13 when counted from the carboxyl end.
14. Question: What do the numbers and Δ symbol represent in fatty acid nomenclature? Answer: C:D(Δpositions) identifies the number of carbons (C), the number of double bonds (D), and the double-bond positions counted from the carboxyl carbon (C1).
15. Question: How do you convert delta notation to omega notation for a polyunsaturated fatty acid? Answer: Omega family = total carbons − highest Δ position. For 18:2(Δ9,12), 18 − 12 = 6, making it an ω-6 fatty acid. The omega designation locates the first double bond from the methyl end.
16. Question: What is the common name of 18:2(Δ9,12), and how does it differ from 18:3(Δ9,12,15)? Answer: 18:2(Δ9,12) is linoleic acid (ω-6); 18:3(Δ9,12,15) is α-linolenic acid (ω-3). Both are essential fatty acids because humans cannot introduce the required double bonds beyond Δ9 toward the methyl end.
17. Question: Study Guide Question: What is the function of perilipin phosphorylation in adipocytes? Answer: Perilipin phosphorylation by PKA permits lipases to access stored TAGs and releases CGI-58 to activate ATGL, promoting lipolysis.
18. Question: How do perilipins regulate access to stored triacylglycerols? Answer: Unphosphorylated perilipins coat lipid droplets and restrict lipase access. PKA-mediated phosphorylation reorganizes the droplet surface, allowing ATGL and HSL to mobilize fatty acids.
19. Question: What is the complete hormonal mechanism connecting perilipin phosphorylation to adipocyte lipolysis? Answer: Epinephrine/glucagon → Gs-coupled receptor → adenylyl cyclase activation → ATP converted to cAMP → PKA activation → phosphorylation of perilipin and HSL. Phosphorylated perilipin releases CGI-58, which activates ATGL: TAG → DAG + fatty acid. Phosphorylated HSL acts on DAG → MAG + fatty acid. Monoacylglycerol lipase (MGL) converts MAG → glycerol + fatty acid. Overall: TAG + 3H₂O → glycerol + 3 fatty acids.
20. Question: Which enzymes sequentially hydrolyze TAGs during hormone-stimulated lipolysis, and which performs the first step? Answer: ATGL: TAG → DAG; HSL: DAG → MAG; MGL: MAG → glycerol. ATGL performs the initial TAG hydrolysis, while HSL primarily hydrolyzes DAG.
21. Question: Study Guide Question: What lipid-related abnormality is associated with Refsum disease? Answer: Accumulation of phytanic acid in blood and tissues due to defective peroxisomal α-oxidation.
22. Question: What enzyme deficiency causes classical Refsum disease, and why does phytanic acid accumulate? Answer: Deficiency of phytanoyl-CoA hydroxylase (phytanoyl-CoA 2-hydroxylase) prevents the α-hydroxylation required to remove phytanic acid's obstructing carboxyl-end carbon.
23. Question: How does defective α-oxidation produce phytanic acid accumulation in Refsum disease? Answer: Normal pathway: phytanic acid → phytanoyl-CoA → 2-hydroxyphytanoyl-CoA → pristanal → pristanic acid → peroxisomal β-oxidation. A defective phytanoyl-CoA hydroxylase blocks the first α-oxidation-specific reaction, while the β-methyl group prevents an alternative direct β-oxidation route. Phytanic acid consequently accumulates.
24. Question: How can Refsum disease be distinguished from X-linked adrenoleukodystrophy based on accumulated fatty acids? Answer: Refsum disease causes phytanic acid accumulation due to defective α-oxidation. X-linked adrenoleukodystrophy causes very-long-chain fatty acid accumulation, especially C26:0, due to defective peroxisomal fatty acid transport and β-oxidation.
25. Question: Study Guide Question: In which cellular compartment does omega-oxidation of fatty acids occur? Answer: The endoplasmic reticulum, primarily in liver and kidney cells.
26. Question: How does ω-oxidation differ from α-oxidation and β-oxidation? Answer: ω-Oxidation targets the terminal methyl carbon in the ER; α-oxidation removes one carboxyl-end carbon in peroxisomes; β-oxidation removes two-carbon units from the carboxyl end, primarily in mitochondria.
27. Question: What is the complete ω-oxidation pathway, including enzymes, substrates, and reducing equivalents? Answer: Fatty acid terminal −CH₃ → −CH₂OH → −CHO → −COOH. First, ER cytochrome P450 monooxygenase converts the ω-methyl group into an alcohol using NADPH + H⁺ + O₂ → NADP⁺ + H₂O while incorporating one oxygen atom into the substrate. Second, alcohol dehydrogenase oxidizes the alcohol to an aldehyde using NAD⁺ → NADH + H⁺. Third, aldehyde dehydrogenase oxidizes the aldehyde to a second carboxyl group using NAD⁺ + H₂O → NADH + H⁺. The resulting dicarboxylic acid can undergo β-oxidation from its carboxyl ends, generating shorter dicarboxylic acids such as succinate or adipate.
28. Question: Under what conditions does ω-oxidation become especially important, and which urinary metabolites can indicate increased activity? Answer: When mitochondrial β-oxidation or the carnitine shuttle is impaired, ω-oxidation increases. Dicarboxylic acids, including adipate, may accumulate in urine.
29. Question: Study Guide Question: Where in the body is β-hydroxybutyrate formed from fatty acids? Answer: Primarily in the liver, where fatty acid-derived acetyl-CoA undergoes ketogenesis in hepatocyte mitochondria.
30. Question: Why does the liver convert fatty acid-derived acetyl-CoA into β-hydroxybutyrate? Answer: During fasting or carbohydrate deficiency, oxaloacetate is diverted toward gluconeogenesis, limiting TCA-cycle oxidation of acetyl-CoA. The liver therefore converts excess acetyl-CoA into transportable ketone bodies.
31. Question: What is the complete biochemical pathway for forming β-hydroxybutyrate from fatty acids? Answer: Fatty acyl-CoA → repeated β-oxidation → acetyl-CoA + NADH + FADH₂. Two acetyl-CoA molecules condense via thiolase → acetoacetyl-CoA + CoA. Acetoacetyl-CoA + acetyl-CoA + H₂O → HMG-CoA + CoA via mitochondrial HMG-CoA synthase. HMG-CoA → acetoacetate + acetyl-CoA via HMG-CoA lyase. Acetoacetate + NADH + H⁺ ⇌ D-β-hydroxybutyrate + NAD⁺ via D-β-hydroxybutyrate dehydrogenase. The product is released into blood.
32. Question: What determines whether acetoacetate or β-hydroxybutyrate predominates during hepatic ketogenesis? Answer: The mitochondrial NADH/NAD⁺ ratio. A high NADH/NAD⁺ ratio favors reduction of acetoacetate to β-hydroxybutyrate, which is generally the predominant circulating ketone body.
33. Question: Study Guide Question: In which cellular compartment are ketone bodies synthesized? Answer: The mitochondrial matrix of liver cells (hepatocytes).
34. Question: How does the location of ketone body synthesis differ from cholesterol synthesis despite both pathways using HMG-CoA? Answer: Ketogenesis uses mitochondrial HMG-CoA synthase and HMG-CoA lyase; cholesterol synthesis uses cytosolic HMG-CoA synthase and ER-associated HMG-CoA reductase. The HMG-CoA pools serve distinct pathways.
35. Question: What are the enzymes and reactions involved in hepatic ketone body synthesis? Answer: 2 acetyl-CoA → acetoacetyl-CoA + CoA (thiolase); acetoacetyl-CoA + acetyl-CoA + H₂O → HMG-CoA + CoA (mitochondrial HMG-CoA synthase); HMG-CoA → acetoacetate + acetyl-CoA (HMG-CoA lyase); acetoacetate + NADH + H⁺ ⇌ D-β-hydroxybutyrate + NAD⁺ (β-hydroxybutyrate dehydrogenase). Acetoacetate can also undergo decarboxylation → acetone + CO₂.
36. Question: Which ketogenesis enzyme is particularly important for controlling ketone body production, and what happens to ketogenesis when insulin is low? Answer: Mitochondrial HMG-CoA synthase is a major regulatory enzyme of ketogenesis. Low insulin and increased glucagon promote fatty acid mobilization and hepatic β-oxidation, increasing acetyl-CoA availability for ketogenesis.
37. Question: Study Guide Question: What role does serum albumin play in transporting fatty acids in the bloodstream? Answer: Serum albumin noncovalently binds free fatty acids released from adipose tissue and transports them through blood to energy-consuming tissues.
38. Question: Why must nonesterified fatty acids bind to albumin during circulation? Answer: Fatty acids are poorly soluble in aqueous plasma. Albumin contains approximately seven high-affinity fatty acid-binding sites that shield hydrophobic hydrocarbon chains from water.
39. Question: What is the pathway for fatty acid transport from stored TAGs to oxidation in peripheral tissues? Answer: Adipocyte TAG → fatty acids + glycerol by ATGL, HSL, and MGL → fatty acids enter blood and bind albumin noncovalently → albumin delivers fatty acids to muscle, heart, or other tissues → fatty acids dissociate and enter cells → acyl-CoA synthetase uses ATP + CoA → AMP + PPi + fatty acyl-CoA → long-chain acyl groups enter mitochondria using CPT-I, CACT, and CPT-II → β-oxidation yields acetyl-CoA, NADH, and FADH₂.
40. Question: How are free fatty acids and triacylglycerols transported differently through the bloodstream? Answer: Free fatty acids travel bound to serum albumin, whereas triacylglycerols travel within lipoproteins such as chylomicrons and VLDL. Albumin is not the principal carrier of circulating TAGs.
41. Question: Study Guide Question: Which electron carriers are involved in the β-oxidation of long-chain fatty acids? Answer: FAD and NAD⁺, which are reduced to FADH₂ and NADH, respectively; FAD-derived electrons pass through ETF to the respiratory chain.
42. Question: Why does β-oxidation require both FAD and NAD⁺? Answer: FAD accepts electrons during the first oxidation of fatty acyl-CoA to trans-Δ²-enoyl-CoA, while NAD⁺ accepts electrons during oxidation of L-β-hydroxyacyl-CoA to β-ketoacyl-CoA.
43. Question: What is the complete β-oxidation reaction sequence and the fate of each reducing equivalent? Answer: 1. Oxidation: fatty acyl-CoA → trans-Δ²-enoyl-CoA by acyl-CoA dehydrogenase, reducing enzyme-bound FAD; electrons pass to electron-transfer flavoprotein (ETF) → ETF:ubiquinone oxidoreductase → CoQ → Complex III → Complex IV → O₂, yielding approximately 1.5 ATP per electron pair. 2. Hydration: trans-Δ²-enoyl-CoA + H₂O → L-β-hydroxyacyl-CoA via enoyl-CoA hydratase. 3. Oxidation: L-β-hydroxyacyl-CoA + NAD⁺ → β-ketoacyl-CoA + NADH + H⁺ via β-hydroxyacyl-CoA dehydrogenase; NADH transfers electrons through Complex I, yielding approximately 2.5 ATP. 4. Thiolysis: β-ketoacyl-CoA + CoA → acetyl-CoA + fatty acyl-CoA shortened by two carbons via thiolase.
44. Question: How do electron transport pathways differ for mitochondrial FAD-derived and NADH-derived electrons during β-oxidation? Answer: FAD-derived electrons enter through ETF and ETF:ubiquinone oxidoreductase at CoQ, bypassing Complex I; NADH electrons enter through Complex I. Their approximate ATP yields are 1.5 and 2.5, respectively.
45. Question: Study Guide Question: Which fatty acids cannot be properly metabolized in individuals with vitamin B12 deficiency? Answer: Odd-chain fatty acids, because their propionyl-CoA product requires B12-dependent methylmalonyl-CoA mutase for conversion to succinyl-CoA.
46. Question: Why is vitamin B12 particularly important for complete oxidation of odd-chain fatty acids? Answer: Odd-chain fatty acids yield propionyl-CoA rather than only acetyl-CoA. The conversion of L-methylmalonyl-CoA to succinyl-CoA requires 5′-deoxyadenosylcobalamin (coenzyme B12).
47. Question: What is the complete pathway converting odd-chain fatty acid-derived propionyl-CoA into a TCA-cycle intermediate? Answer: Odd-chain fatty acyl-CoA → repeated β-oxidation → acetyl-CoA + propionyl-CoA (3C). Propionyl-CoA + HCO₃⁻ + ATP → D-methylmalonyl-CoA + ADP + Pi via propionyl-CoA carboxylase, requiring biotin. D-methylmalonyl-CoA ⇌ L-methylmalonyl-CoA via methylmalonyl-CoA epimerase. L-methylmalonyl-CoA → succinyl-CoA via methylmalonyl-CoA mutase, requiring 5′-deoxyadenosylcobalamin (vitamin B12). Succinyl-CoA enters the TCA cycle.
48. Question: Which metabolic pathways besides odd-chain fatty acid oxidation can be impaired by vitamin B12 deficiency? Answer: Breakdown of branched-chain substrates that generate propionyl-CoA, including certain branched-chain fatty acids and amino acids such as valine, isoleucine, methionine, and threonine. B12 deficiency also impairs methionine synthase, a separate reaction.
49. Question: Study Guide Question: Can acetyl-CoA from fatty acid oxidation be used for both energy production and ketone body synthesis in liver cells? Answer: Yes. Hepatic acetyl-CoA can enter the TCA cycle for energy production or undergo ketogenesis to produce ketone bodies.
50. Question: What determines whether hepatic fatty acid-derived acetyl-CoA enters the TCA cycle or ketogenesis? Answer: Oxaloacetate availability and acetyl-CoA accumulation. Adequate TCA-cycle intermediates favor oxidation for energy; depletion of oxaloacetate during gluconeogenesis favors ketone body synthesis.
51. Question: How does fatty acid-derived acetyl-CoA enter either ATP production or ketone body synthesis in the liver? Answer: Fatty acids → fatty acyl-CoA → mitochondrial β-oxidation → acetyl-CoA + NADH + FADH₂. Energy route: acetyl-CoA + oxaloacetate → citrate via citrate synthase → TCA cycle → 3 NADH + FADH₂ + GTP per acetyl-CoA → electron transport chain → ATP. Ketogenesis route: 2 acetyl-CoA → acetoacetyl-CoA via thiolase → HMG-CoA via mitochondrial HMG-CoA synthase → acetoacetate via HMG-CoA lyase → β-hydroxybutyrate using NADH or acetone by decarboxylation.
52. Question: Can the liver use the ketone bodies it synthesizes for energy, and why? Answer: No. The liver lacks β-ketoacyl-CoA transferase (thiophorase/SCOT), which is required for ketone body utilization. It can oxidize fatty acids directly but exports ketone bodies for extrahepatic tissues.
53. Question: Study Guide Question: Which fatty acid derivatives can cross the inner mitochondrial membrane? Answer: Fatty acylcarnitines, which cross through carnitine-acylcarnitine translocase; long-chain fatty acyl-CoA cannot cross directly.
54. Question: Why are fatty acyl groups transported across the inner mitochondrial membrane as carnitine esters rather than CoA thioesters? Answer: The inner mitochondrial membrane is impermeable to long-chain fatty acyl-CoA. Carnitine allows transport of the acyl group while keeping the cytosolic and mitochondrial CoA pools separate.
55. Question: What reactions convert fatty acyl-CoA to a membrane-transportable derivative and regenerate it in the matrix? Answer: Fatty acyl-CoA + carnitine ⇌ fatty acylcarnitine + CoA via CPT-I on the outer mitochondrial membrane. CACT imports acylcarnitine while exporting free carnitine. Fatty acylcarnitine + matrix CoA ⇌ fatty acyl-CoA + carnitine via CPT-II on the matrix-facing inner mitochondrial membrane. Carnitine is returned through CACT, and the regenerated fatty acyl-CoA undergoes β-oxidation.
56. Question: Can acetyl-CoA or long-chain fatty acyl-CoA directly cross the inner mitochondrial membrane? Answer: No. Long-chain acyl groups use the carnitine shuttle. Acetyl units can be transferred indirectly through other pathways, such as citrate export for cytosolic acetyl-CoA generation.
57. Question: Study Guide Question: What is the role of perilipins in regulating lipid droplet metabolism? Answer: Perilipins coat lipid droplets and restrict premature lipolysis; phosphorylation permits lipase access and promotes regulated fatty acid mobilization.
58. Question: What is the structural role of perilipins in adipocyte lipid droplets? Answer: Perilipins associate with the phospholipid monolayer surrounding the TAG- and cholesteryl ester-rich core, controlling access of lipolytic enzymes to stored lipids.
59. Question: How does perilipin regulate the activation of ATGL and hormone-sensitive lipase? Answer: Resting state: unphosphorylated perilipin binds CGI-58 and restricts lipase access. Hormonal stimulation → Gs → adenylyl cyclase → cAMP → PKA → perilipin phosphorylation → CGI-58 dissociates and activates ATGL, catalyzing TAG → DAG + fatty acid. Phosphorylated HSL associates with the droplet and hydrolyzes DAG → MAG + fatty acid; MGL completes MAG hydrolysis.
60. Question: Do perilipins directly hydrolyze TAGs, and which enzymes actually catalyze lipid droplet lipolysis? Answer: No. Perilipins are regulatory coating proteins, not lipases. ATGL, HSL, and MGL catalyze sequential TAG breakdown.
61. Question: Study Guide Question: What are the products of a single cycle of β-oxidation converting palmitoyl-CoA to myristoyl-CoA? Answer: Myristoyl-CoA (C14), acetyl-CoA (C2), FADH₂, NADH, and H⁺. The cycle consumes one CoA, one FAD, one NAD⁺, and one H₂O.
62. Question: Why does one β-oxidation cycle shorten palmitoyl-CoA from 16 carbons to myristoyl-CoA with 14 carbons? Answer: Thiolase removes a two-carbon acetyl-CoA unit from the carboxyl end, leaving a fatty acyl-CoA shortened by two carbons. The initial cycle does not fully oxidize the remaining 14-carbon chain.
63. Question: What are the four reactions and overall stoichiometry for one cycle of palmitoyl-CoA β-oxidation? Answer: Palmitoyl-CoA → trans-Δ²-hexadecenoyl-CoA via acyl-CoA dehydrogenase, reducing FAD → FADH₂ equivalents transferred through ETF. Trans-Δ²-hexadecenoyl-CoA + H₂O → L-3-hydroxyhexadecanoyl-CoA via enoyl-CoA hydratase. L-3-hydroxyhexadecanoyl-CoA + NAD⁺ → 3-ketohexadecanoyl-CoA + NADH + H⁺ via β-hydroxyacyl-CoA dehydrogenase. 3-Ketohexadecanoyl-CoA + CoA → myristoyl-CoA + acetyl-CoA via thiolase. Overall: palmitoyl-CoA + CoA + FAD + NAD⁺ + H₂O → myristoyl-CoA + acetyl-CoA + FADH₂ + NADH + H⁺.
64. Question: How many β-oxidation cycles, acetyl-CoA molecules, FADH₂ equivalents, and NADH molecules result from complete β-oxidation of palmitoyl-CoA? Answer: 7 cycles, 8 acetyl-CoA, 7 FADH₂ equivalents, and 7 NADH. Seven successive two-carbon removals leave two final carbons that form the eighth acetyl-CoA.
65. Question: Study Guide Question: Which compounds are classified as ketone bodies? Answer: Acetoacetate, D-β-hydroxybutyrate, and acetone.
66. Question: What distinguishes the three ketone bodies in terms of structure and metabolic function? Answer: Acetoacetate is a ketone and usable fuel; β-hydroxybutyrate is a hydroxy acid and usable fuel; acetone is a volatile ketone primarily eliminated through exhalation.
67. Question: How are the three ketone bodies synthesized from acetyl-CoA? Answer: 2 acetyl-CoA → acetoacetyl-CoA (thiolase) → HMG-CoA (mitochondrial HMG-CoA synthase, requiring another acetyl-CoA and H₂O) → acetoacetate + acetyl-CoA (HMG-CoA lyase). Acetoacetate + NADH + H⁺ ⇌ D-β-hydroxybutyrate + NAD⁺ (β-hydroxybutyrate dehydrogenase). Alternatively, acetoacetate → acetone + CO₂ through spontaneous or enzymatic decarboxylation.
68. Question: Which ketone body is not chemically a ketone, and which is generally most abundant during ketosis? Answer: D-β-hydroxybutyrate is not technically a ketone because it contains a hydroxyl rather than a ketone group; it is generally the predominant circulating ketone body.
69. Question: Study Guide Question: Which tissues are unable to use ketone bodies as an energy source? Answer: The liver and red blood cells. The liver lacks thiophorase (SCOT), while mature erythrocytes lack mitochondria.
70. Question: Why can the liver synthesize ketone bodies but not utilize them as a major energy source? Answer: Hepatocytes lack succinyl-CoA:acetoacetate CoA transferase (SCOT/thiophorase), the enzyme that activates acetoacetate to acetoacetyl-CoA during ketolysis.
71. Question: What is the complete ketone body utilization pathway in extrahepatic tissues? Answer: D-β-hydroxybutyrate + NAD⁺ → acetoacetate + NADH + H⁺ via β-hydroxybutyrate dehydrogenase. Acetoacetate + succinyl-CoA → acetoacetyl-CoA + succinate via SCOT (thiophorase). Acetoacetyl-CoA + CoA → 2 acetyl-CoA via thiolase. Both acetyl-CoA molecules enter the TCA cycle, producing NADH, FADH₂, and GTP; NADH and FADH₂ subsequently drive oxidative phosphorylation.
72. Question: Can the brain use ketone bodies, and why can mature erythrocytes not use them? Answer: The brain can use acetoacetate and β-hydroxybutyrate, particularly during prolonged fasting. Mature erythrocytes cannot because they lack mitochondria and rely on glycolysis for ATP production.
73. Question: Study Guide Question: What is the major regulatory enzyme controlling the β-oxidation pathway? Answer: Carnitine palmitoyltransferase I (CPT-I/CAT-I) controls the rate-limiting entry of long-chain fatty acyl groups into mitochondria and is inhibited by malonyl-CoA.
74. Question: Why is CPT-I considered the major control point for long-chain fatty acid β-oxidation? Answer: CPT-I determines whether long-chain fatty acyl groups can enter the mitochondrial matrix for oxidation. Its inhibition by malonyl-CoA coordinates fatty acid synthesis with fatty acid breakdown.
75. Question: How does malonyl-CoA regulate mitochondrial β-oxidation through CPT-I? Answer: Fed state → insulin and citrate activate acetyl-CoA carboxylase (ACC) → acetyl-CoA + HCO₃⁻ + ATP → malonyl-CoA → malonyl-CoA inhibits CPT-I → decreased fatty acylcarnitine formation → decreased mitochondrial fatty acid entry → decreased β-oxidation. Fasting → glucagon and increased AMP favor ACC phosphorylation and inhibition → malonyl-CoA decreases → CPT-I inhibition is relieved → fatty acylcarnitine formation and β-oxidation increase.
76. Question: Which enzymes regulate fatty acid oxidation directly versus indirectly, and which is the main exam-relevant control point? Answer: CPT-I directly controls mitochondrial entry of long-chain fatty acyl groups; ACC indirectly regulates it by producing inhibitory malonyl-CoA. PPARα also regulates expression of β-oxidation enzymes, but CPT-I-mediated transport is the main rate-limiting control point emphasized in the lecture.
77. Question: Study Guide Question: Which metabolic intermediates are produced from the oxidation of odd-numbered fatty acids? Answer: Acetyl-CoA and propionyl-CoA; propionyl-CoA is subsequently converted into succinyl-CoA.
78. Question: Why do odd-chain fatty acids generate propionyl-CoA in addition to acetyl-CoA? Answer: β-Oxidation removes two-carbon acetyl-CoA units until a three-carbon fragment remains. This final fragment is propionyl-CoA, which can be converted into the TCA-cycle intermediate succinyl-CoA.
79. Question: What is the complete β-oxidation and propionyl-CoA metabolism pathway for odd-chain fatty acids? Answer: Odd-chain fatty acyl-CoA → repeated β-oxidation → acetyl-CoA + propionyl-CoA. Each β-oxidation cycle generates one NADH and FADH₂ equivalent. Propionyl-CoA + HCO₃⁻ + ATP → D-methylmalonyl-CoA + ADP + Pi via propionyl-CoA carboxylase, requiring biotin. D-methylmalonyl-CoA → L-methylmalonyl-CoA via epimerase → succinyl-CoA via methylmalonyl-CoA mutase, requiring coenzyme B12 (adenosylcobalamin) → TCA cycle.
80. Question: Which cofactors are required for conversion of propionyl-CoA into succinyl-CoA, and what happens when they are deficient? Answer: Biotin and ATP are required by propionyl-CoA carboxylase; vitamin B12 is required by methylmalonyl-CoA mutase. Biotin-dependent enzyme defects can cause propionic acidemia, while B12 deficiency can cause methylmalonyl-CoA and methylmalonic acid accumulation.
81. Question: Study Guide Question: Where is radiolabeled methyl carbon from a fatty acid most likely recovered after β-oxidation? Answer: In the final acetyl-CoA molecule produced by β-oxidation. If subsequently oxidized through the TCA cycle, the label can ultimately appear in CO₂.
82. Question: Why does a radiolabeled terminal methyl carbon remain until the final stages of fatty acid β-oxidation? Answer: β-Oxidation removes two-carbon acetyl-CoA units from the carboxyl end, not the methyl end. Therefore, the original terminal methyl carbon remains in the shrinking fatty acyl chain until the final acetyl-CoA is generated.
83. Question: What is the fate of the terminal methyl carbon of radiolabeled palmitate during complete β-oxidation and subsequent metabolism? Answer: Palmitate C16 (terminal methyl) → palmitoyl-CoA → seven β-oxidation cycles removing successive two-carbon units from the carboxyl end → final acetyl-CoA containing original carbons C15–C16. This acetyl-CoA can enter the TCA cycle by condensation with oxaloacetate via citrate synthase → citrate → successive oxidation and decarboxylation reactions → eventual recovery of the radiolabel as CO₂. β-Oxidation itself does not release the fatty acid's carbon atoms as CO₂.
84. Question: How does radiolabel recovery differ when the labeled carbon is at the carboxyl end versus the methyl end of palmitate? Answer: Carboxyl-end carbons (C1–C2) enter the first acetyl-CoA released; methyl-end carbons (C15–C16) remain until the final acetyl-CoA. Either labeled acetyl group can eventually yield labeled CO₂ through continued metabolism.
85. Question: Study Guide Question: What enzyme catalyzes the first oxidation step in β-oxidation, and what chemical transformation occurs? Answer: Acyl-CoA dehydrogenase converts fatty acyl-CoA into trans-Δ²-enoyl-CoA by introducing a double bond between the α- and β-carbons, reducing FAD.
86. Question: Why does acyl-CoA dehydrogenase introduce a double bond between carbons 2 and 3 of fatty acyl-CoA? Answer: The α–β double bond enables hydration and subsequent oxidation to a β-ketoacyl-CoA intermediate, which can undergo thiolytic cleavage to release acetyl-CoA.
87. Question: What are the chemical reactions and electron-transfer pathway associated with the first β-oxidation step? Answer: Saturated fatty acyl-CoA → trans-Δ²-enoyl-CoA via acyl-CoA dehydrogenase. Hydrogen atoms are removed from C2 (α-carbon) and C3 (β-carbon), creating a trans double bond. Enzyme-bound FAD accepts two electrons and two protons, forming FADH₂ equivalents. Electrons pass from acyl-CoA dehydrogenase → ETF → ETF:ubiquinone oxidoreductase → CoQ → Complex III → cytochrome c → Complex IV → O₂, generating approximately 1.5 ATP through oxidative phosphorylation.
88. Question: What are the different acyl-CoA dehydrogenase isoenzymes, and what happens in MCAD deficiency? Answer: Very-long-chain, long-chain, medium-chain, and short-chain acyl-CoA dehydrogenases act on different chain lengths. MCAD deficiency primarily impairs oxidation of medium-chain fatty acids, especially C6–C12, causing fasting intolerance, hypoketotic hypoglycemia, and accumulation of medium-chain fatty acid metabolites.
89. Question: Study Guide Question: How much ATP is generated from the complete oxidation of one molecule of palmitate? Answer: 106 net ATP, accounting for seven β-oxidation cycles, eight acetyl-CoA molecules entering the TCA cycle, and two ATP equivalents used for activation.
90. Question: Why does complete palmitate oxidation produce 106 net ATP rather than 108 ATP? Answer: Complete oxidation yields 108 ATP equivalents before activation costs. Converting palmitate to palmitoyl-CoA consumes ATP → AMP + PPi, equivalent to two ATP high-energy phosphate bonds, leaving 106 net ATP.
91. Question: What is the full ATP yield calculation for complete oxidation of palmitate (16:0)? Answer: Palmitate (C16) → 7 β-oxidation cycles → 8 acetyl-CoA + 7 NADH + 7 FADH₂ equivalents. β-Oxidation: 7 NADH × 2.5 ATP = 17.5 ATP; 7 FADH₂ × 1.5 ATP = 10.5 ATP, totaling 28 ATP. TCA cycle: each acetyl-CoA generates 3 NADH, 1 FADH₂, and 1 GTP, equal to 10 ATP × 8 = 80 ATP. Gross = 28 + 80 = 108 ATP. Fatty acid activation costs 2 ATP equivalents. Net = 106 ATP.
92. Question: What general formulas determine β-oxidation cycles, acetyl-CoA production, and ATP yield for an even-chain saturated fatty acid? Answer: For a saturated even-chain fatty acid with n carbons: β-oxidation cycles = n/2 − 1; acetyl-CoA = n/2; NADH = FADH₂ = n/2 − 1. Net ATP = 10(n/2) + 4(n/2 − 1) − 2, assuming 2.5 ATP/NADH and 1.5 ATP/FADH₂.
93. Question: Study Guide Question: Which metabolite regulates the activity of carnitine acyltransferase 1? Answer: Malonyl-CoA, which inhibits carnitine acyltransferase I (CPT-I) and decreases mitochondrial fatty acid entry.
94. Question: Why does malonyl-CoA inhibit CPT-I during fatty acid synthesis? Answer: Malonyl-CoA signals active fatty acid biosynthesis. Inhibiting CPT-I prevents newly synthesized fatty acids from immediately entering mitochondria for degradation, avoiding futile cycling.
95. Question: How does the synthesis and degradation of malonyl-CoA coordinate fatty acid synthesis with oxidation? Answer: High-energy/fed state: acetyl-CoA + HCO₃⁻ + ATP → malonyl-CoA via ACC, requiring biotin → CPT-I inhibition → less fatty acylcarnitine → reduced β-oxidation. Low-energy/fasting state: AMP activates AMPK, which phosphorylates and inhibits ACC → malonyl-CoA falls; malonyl-CoA decarboxylase can further degrade malonyl-CoA → CPT-I activity increases → fatty acylcarnitine transport → mitochondrial β-oxidation.
96. Question: How do ACC1 and ACC2 differ in their roles in fatty acid metabolism? Answer: ACC1 is primarily cytosolic and generates malonyl-CoA for de novo fatty acid synthesis; ACC2 is associated with the outer mitochondrial membrane and generates malonyl-CoA that inhibits CPT-I. Both catalyze acetyl-CoA carboxylation.
97. Question: Study Guide Question: Does carnitine deficiency affect the α-oxidation pathway? Answer: No. Peroxisomal α-oxidation itself does not require carnitine, although subsequent mitochondrial oxidation of its products may be affected.
98. Question: Why can α-oxidation occur despite a deficiency in the carnitine shuttle? Answer: α-Oxidation occurs in peroxisomes and uses enzymes distinct from mitochondrial fatty acid transport. Carnitine is primarily required to transfer long-chain fatty acyl groups into the mitochondrial matrix for β-oxidation.
99. Question: What is the α-oxidation pathway that remains functional in the absence of carnitine? Answer: Phytanic acid → phytanoyl-CoA via acyl-CoA synthetase, using ATP and CoA → 2-hydroxyphytanoyl-CoA via phytanoyl-CoA hydroxylase, requiring O₂, Fe²⁺, and α-ketoglutarate → pristanal via TPP-dependent 2-hydroxyacyl-CoA lyase → pristanic acid via NAD⁺-dependent aldehyde dehydrogenase. These α-oxidation reactions occur in peroxisomes without the mitochondrial carnitine shuttle.
100. Question: Which fatty acid oxidation pathway becomes more important during carnitine deficiency, and why? Answer: ER-based ω-oxidation increases when mitochondrial long-chain fatty acid β-oxidation is impaired. Carnitine deficiency does not directly block peroxisomal α-oxidation, but it can reduce subsequent mitochondrial processing of peroxisomal products.
101. Question: Study Guide Question: What types of fatty acids are oxidized in peroxisomes, and what happens to the products? Answer: Very-long-chain and certain branched-chain fatty acids are shortened in peroxisomes; shorter fatty acyl products and acetyl groups are exported for further mitochondrial oxidation.
102. Question: Why are peroxisomes important for the oxidation of very-long-chain fatty acids? Answer: Peroxisomal oxidation enzymes preferentially act on very-long-chain and certain branched fatty acyl-CoAs that are poorly handled by mitochondrial β-oxidation. Peroxisomes shorten these chains but do not contain the TCA-cycle machinery required for complete oxidation.
103. Question: What is the complete peroxisomal β-oxidation pathway, including enzymes, reducing equivalents, and product transport? Answer: 1. Acyl-CoA oxidase: very-long-chain fatty acyl-CoA → trans-Δ²-enoyl-CoA; enzyme-bound FAD-derived electrons transfer directly to O₂ → H₂O₂, without mitochondrial ETC ATP production. Catalase: 2H₂O₂ → 2H₂O + O₂. 2. Enoyl-CoA hydratase: trans-Δ²-enoyl-CoA + H₂O → L-β-hydroxyacyl-CoA. 3. β-Hydroxyacyl-CoA dehydrogenase: L-β-hydroxyacyl-CoA + NAD⁺ → β-ketoacyl-CoA + NADH + H⁺; reducing equivalents are transferred out of the peroxisome for reoxidation. 4. Thiolase: β-ketoacyl-CoA + CoA → acetyl-CoA + fatty acyl-CoA shortened by two carbons.** Shortened acyl groups, often approximately C8 or shorter products depending on substrate, are exported, including as carnitine esters, for further mitochondrial metabolism.
104. Question: What are the main differences between mitochondrial and peroxisomal β-oxidation? Answer: Mitochondrial β-oxidation feeds FAD-derived electrons to ETF and the ETC, producing ATP, whereas peroxisomal acyl-CoA oxidase transfers electrons directly to O₂, forming H₂O₂. Peroxisomes preferentially shorten very-long-chain fatty acids; catalase removes H₂O₂, and mitochondrial metabolism completes oxidation.
105. Question: Study Guide Question: What is the role of apolipoprotein B-48 in lipid transport? Answer: ApoB-48 is the major structural apolipoprotein of intestinal chylomicrons, allowing packaging and transport of dietary lipids.
106. Question: How does apolipoprotein B-48 differ from apolipoprotein B-100? Answer: ApoB-48 is synthesized in intestinal cells through RNA editing and forms chylomicrons; ApoB-100 is synthesized in the liver, is present in VLDL and LDL, and binds the LDL receptor.
107. Question: What is the pathway by which ApoB-48-containing chylomicrons transport dietary lipids? Answer: Dietary TAGs → intestinal lipase hydrolysis → fatty acids + monoacylglycerols → enterocytes → TAG re-esterification in the ER → packaging with ApoB-48 by microsomal triglyceride transfer protein (MTP) → chylomicrons → intestinal lymph → bloodstream. Chylomicrons acquire ApoC-II and ApoE from HDL → ApoC-II activates capillary LPL, releasing fatty acids → chylomicron remnants containing ApoB-48 and ApoE → hepatic ApoE-dependent receptor-mediated endocytosis.
108. Question: Does ApoB-48 bind the LDL receptor, and which apolipoprotein mediates chylomicron remnant clearance? Answer: ApoB-48 does not contain the functional ApoB-100 LDL receptor-binding region. ApoE mediates hepatic clearance of chylomicron remnants through ApoE-recognizing receptors.
109. Question: Study Guide Question: What type of inhibitor is acetylsalicylic acid (aspirin) for the COX-2 enzyme? Answer: An irreversible covalent inhibitor, which acetylates an active-site serine residue and inhibits cyclooxygenase activity.
110. Question: Why is aspirin classified as an irreversible inhibitor rather than a reversible competitive inhibitor? Answer: Aspirin transfers an acetyl group to an essential serine residue of COX, forming a covalent modification that persistently blocks cyclooxygenase activity. Recovery generally requires synthesis of new enzyme.
111. Question: What is the biochemical mechanism by which aspirin inhibits prostaglandin and thromboxane synthesis? Answer: Membrane phospholipids → arachidonic acid via phospholipase A₂. Ordinarily, arachidonic acid + 2O₂ → PGG₂ via COX cyclooxygenase activity; PGG₂ is subsequently reduced to PGH₂ by COX peroxidase activity, supplying precursors for prostaglandins and thromboxanes. Aspirin covalently acetylates an essential serine in the cyclooxygenase active site, irreversibly suppressing arachidonate conversion to PGG₂ and thereby decreasing PGH₂-derived products. It inhibits both COX-1 and COX-2.
112. Question: How does aspirin differ from ibuprofen and naproxen, and does aspirin inhibit leukotriene synthesis? Answer: Aspirin is an irreversible covalent COX inhibitor; ibuprofen and naproxen are reversible COX inhibitors. Aspirin inhibits prostaglandin and thromboxane synthesis but does not directly inhibit the lipoxygenase pathway producing leukotrienes.
113. Question: Study Guide Question: What is the 30-carbon precursor molecule for steroid biosynthesis? Answer: Squalene (C30), a linear precursor formed from six activated isoprene units that is subsequently cyclized into the sterol ring system.
114. Question: Why is squalene considered a key precursor in cholesterol and steroid biosynthesis? Answer: Squalene is a linear 30-carbon isoprenoid assembled from six five-carbon isoprene units. Its epoxidation and cyclization produce lanosterol, which is subsequently converted into cholesterol, the precursor of steroid hormones.
115. Question: What is the complete biosynthetic pathway from acetyl-CoA to squalene and the first cyclic sterol? Answer: 2 acetyl-CoA → acetoacetyl-CoA via thiolase → HMG-CoA via cytosolic HMG-CoA synthase with a third acetyl-CoA → mevalonate via ER-associated HMG-CoA reductase, consuming 2 NADPH + 2H⁺ and releasing 2 NADP⁺ + CoA. Mevalonate → phosphorylated mevalonate intermediates via three ATP-dependent steps → isopentenyl pyrophosphate (IPP) with decarboxylation → dimethylallyl pyrophosphate (DMAPP) via isomerase. DMAPP + IPP → geranyl pyrophosphate (C10); geranyl pyrophosphate + IPP → farnesyl pyrophosphate (C15). Two farnesyl pyrophosphate molecules + NADPH → squalene (C30) via squalene synthase. Squalene + O₂ + NADPH → squalene 2,3-epoxide via squalene monooxygenase → lanosterol via oxidosqualene cyclase → cholesterol through subsequent reactions.
116. Question: How are squalene, lanosterol, and cholesterol distinguished by structure and biosynthetic order? Answer: Squalene is a linear C30 isoprenoid; lanosterol is the first cyclic C30 sterol; cholesterol is a C27 sterol formed after further processing. The sequence is squalene → squalene epoxide → lanosterol → cholesterol.
117. Question: Study Guide Question: What important lipid molecule is synthesized from palmitoyl-CoA? Answer: Sphingolipids, beginning with sphinganine and progressing to ceramide (N-acylsphingosine), the precursor of sphingomyelin and glycosphingolipids.
118. Question: Why is palmitoyl-CoA important for sphingolipid biosynthesis? Answer: Palmitoyl-CoA condenses with serine to initiate synthesis of the 18-carbon sphingoid backbone. This produces sphinganine, which is converted into ceramide, a central intermediate in sphingolipid synthesis.
119. Question: What is the complete sphingolipid synthesis pathway beginning with palmitoyl-CoA? Answer: Palmitoyl-CoA (C16) + L-serine → 3-ketosphinganine (C18) + CO₂ + CoA, catalyzed by serine palmitoyltransferase, requiring pyridoxal phosphate (PLP). 3-Ketosphinganine + NADPH + H⁺ → sphinganine + NADP⁺ via 3-ketosphinganine reductase. Sphinganine + fatty acyl-CoA → dihydroceramide + CoA via ceramide synthase, forming an amide bond. Dihydroceramide → ceramide via desaturation requiring O₂ and reducing equivalents from NADPH. Ceramide can then form sphingomyelin by acquiring a phosphocholine head group or glycosphingolipids by acquiring carbohydrate head groups. Early steps occur in the ER; later head-group modification largely occurs in the Golgi.
120. Question: What is the major precursor for sphingomyelin and glycosphingolipid synthesis, and how does it relate to palmitoyl-CoA? Answer: Ceramide is the immediate common precursor for sphingomyelin and glycosphingolipids; palmitoyl-CoA is an earlier precursor used to construct the sphingoid backbone. Sphingosine is part of the ceramide structure.
121. Question: Study Guide Question: Which lipoprotein contains the highest percentage of cholesteryl esters? Answer: Low-density lipoprotein (LDL) is particularly enriched in cholesterol and cholesteryl esters.
122. Question: Why does LDL contain a high proportion of cholesterol and cholesteryl esters compared with chylomicrons and VLDL? Answer: Progressive hydrolysis and removal of TAGs from VLDL produces IDL and then LDL, leaving a particle relatively enriched in cholesterol and cholesteryl esters.
123. Question: How is cholesterol transported and concentrated in LDL particles? Answer: Liver TAGs and cholesteryl esters → VLDL secretion → ApoC-II activates LPL → VLDL TAG hydrolysis → IDL → further TAG removal → LDL. LDL contains ApoB-100, which binds LDL receptors → receptor-mediated endocytosis → lysosomal hydrolysis of cholesteryl esters → free cholesterol + fatty acids. LDL delivers cholesterol to peripheral tissues and returns remaining cholesterol to the liver.
124. Question: Which lipoproteins are predominantly enriched in TAGs versus cholesterol, and which enzyme esterifies cholesterol on HDL? Answer: Chylomicrons and VLDL are TAG-rich; LDL is cholesterol/cholesteryl ester-rich; HDL is protein-rich and performs reverse cholesterol transport. LCAT, activated by ApoA-I, esterifies cholesterol on HDL, even though LDL is more enriched in cholesteryl esters by composition.
125. Question: Study Guide Question: What is the precursor molecule for cholesterol synthesis? Answer: Acetyl-CoA, which is converted through HMG-CoA and mevalonate into activated isoprene units used to synthesize cholesterol.
126. Question: Why is acetyl-CoA considered the fundamental precursor of cholesterol biosynthesis? Answer: All carbon atoms of cholesterol originate from two-carbon acetyl units. These are converted into mevalonate and then five-carbon isoprene units before assembly into squalene and cholesterol.
127. Question: What is the complete pathway for cholesterol synthesis beginning with acetyl-CoA? Answer: 2 acetyl-CoA → acetoacetyl-CoA (thiolase) → HMG-CoA (cytosolic HMG-CoA synthase adds a third acetyl-CoA) → mevalonate (HMG-CoA reductase, 2 NADPH → 2 NADP⁺) → phosphorylated mevalonate intermediates (3 ATP consumed) → IPP (C5) through decarboxylation → DMAPP (C5) by isomerization → geranyl-PP (C10) → farnesyl-PP (C15) → squalene (C30) through NADPH-dependent condensation of two farnesyl units → squalene epoxide through O₂/NADPH-dependent monooxygenation → lanosterol through cyclization → cholesterol (C27) through approximately 20 additional reactions including demethylation, reduction, and double-bond rearrangement.
128. Question: How do acetyl-CoA, HMG-CoA, mevalonate, squalene, and lanosterol differ as precursors of cholesterol? Answer: Acetyl-CoA is the initial two-carbon source; HMG-CoA is the substrate of the rate-limiting enzyme; mevalonate is the product of the committed reaction; squalene is the linear C30 intermediate; lanosterol is the first cyclic sterol precursor. Cholesterol itself contains 27 carbons.
129. Question: Study Guide Question: Which lipoproteins are not synthesized by the liver? Answer: Chylomicrons are synthesized in the intestine, while LDL is formed in circulation from VLDL. HDL is synthesized by both the liver and small intestine.
130. Question: How do the sites of origin differ among chylomicrons, VLDL, LDL, and HDL? Answer: Chylomicrons originate in intestinal enterocytes; VLDL originates in hepatocytes; LDL forms through circulating VLDL/IDL metabolism; HDL originates in both the liver and small intestine.
131. Question: What are the formation and transformation pathways of the major circulating lipoproteins? Answer: Exogenous pathway: dietary lipids → intestinal enterocytes → TAG re-esterification → chylomicrons containing ApoB-48 → lymph → blood → ApoC-II activates LPL → fatty acid release → chylomicron remnants → hepatic uptake through ApoE-recognizing receptors. Endogenous pathway: hepatic TAGs and cholesterol → VLDL containing ApoB-100 → blood → LPL-mediated TAG hydrolysis → IDL → further TAG removal → LDL → ApoB-100-mediated LDL receptor binding and uptake. HDL pathway: liver/intestine produce nascent HDL → cholesterol uptake from peripheral cells → LCAT esterifies cholesterol → mature HDL returns cholesterol to liver.
132. Question: Which lipoprotein is produced exclusively in the intestine, and which is produced by modification of another circulating lipoprotein? Answer: Chylomicrons are assembled in intestinal enterocytes; LDL develops from VLDL through IDL in the bloodstream. The liver releases VLDL but does not directly secrete mature LDL.
133. Question: Study Guide Question: What cofactor is required for acetyl-CoA carboxylase activity? Answer: Biotin (vitamin B7), which carries activated CO₂ during the ATP-dependent conversion of acetyl-CoA into malonyl-CoA.
134. Question: Why is biotin required for acetyl-CoA carboxylase activity? Answer: Biotin functions as a covalently attached CO₂ carrier. It accepts a bicarbonate-derived carboxyl group in an ATP-dependent reaction and subsequently transfers that group to acetyl-CoA.
135. Question: What is the complete acetyl-CoA carboxylase reaction, including its enzyme domains, substrates, cofactors, and products? Answer: Step 1: biotin carboxylase activates HCO₃⁻ using ATP and transfers the carboxyl group to enzyme-bound biotin → carboxybiotin + ADP + Pi. Step 2: the biotin carrier domain transports the activated carboxyl group to the carboxyltransferase active site. Step 3: carboxyltransferase transfers CO₂ from carboxybiotin to acetyl-CoA → malonyl-CoA, regenerating biotin. Overall: acetyl-CoA + HCO₃⁻ + ATP → malonyl-CoA + ADP + Pi. Biotin is covalently attached to a lysine residue on ACC and is regenerated, not consumed.
136. Question: Which other metabolic enzymes require biotin, and how does its role differ from NADPH in fatty acid synthesis? Answer: Biotin is required by acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and 3-methylcrotonyl-CoA carboxylase. It transfers CO₂, whereas NADPH supplies reducing equivalents for fatty acid synthase reactions, not the ACC carboxylation step.
137. Question: Study Guide Question: Which apolipoprotein binds to the LDL receptor? Answer: Apolipoprotein B-100 (ApoB-100) is the major LDL apolipoprotein recognized by the LDL receptor.
138. Question: Why can ApoB-100 mediate LDL receptor binding while ApoB-48 cannot? Answer: ApoB-100 contains the receptor-binding domain recognized by LDL receptors. ApoB-48 is a truncated intestinal form lacking this functional region, so its chylomicron remnants rely on ApoE-mediated hepatic recognition.
139. Question: What is the complete LDL receptor-mediated endocytosis pathway? Answer: LDL containing ApoB-100 binds LDLR at the plasma membrane → LDL-LDLR complexes cluster in clathrin-coated pits → clathrin-mediated endocytosis → endosome formation → endosomal acidification promotes LDL dissociation from LDLR → LDLR is sorted into recycling vesicles and returned to the plasma membrane → LDL-containing endosomes mature or fuse with lysosomes → lysosomal acid lipase hydrolyzes cholesteryl esters into free cholesterol + fatty acids → ApoB-100 is degraded to amino acids. Free cholesterol is used in membranes, converted into other sterols, or re-esterified by ACAT for storage.
140. Question: Is ApoB-100 the only apolipoprotein that can interact with LDL receptors? Answer: No. ApoE can also bind LDL receptors and other hepatic remnant receptors. However, ApoB-100 is the primary ligand responsible for ordinary LDL particle recognition by LDLR, while ApoB-48 does not provide LDLR binding.
141. Question: Study Guide Question: Which phospholipids are synthesized using CDP-diacylglycerol, and which are not? Answer: Phosphatidylglycerol, cardiolipin, and phosphatidylinositol use CDP-diacylglycerol. Mammalian phosphatidylcholine and phosphatidylethanolamine primarily use CDP-activated head groups, while mammalian phosphatidylserine uses head-group exchange.
142. Question: What distinguishes CDP-diacylglycerol-dependent phospholipid synthesis from the Kennedy pathway? Answer: CDP-diacylglycerol synthesis activates the lipid backbone with CDP, whereas the Kennedy pathway activates choline or ethanolamine with CDP before attachment to diacylglycerol. Both strategies use cytidine nucleotides to facilitate phosphodiester bond formation.
143. Question: What are the major biosynthetic pathways for phosphatidylglycerol, cardiolipin, phosphatidylinositol, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine? Answer: CDP-DAG pathway: glycerol-3-phosphate + 2 fatty acyl-CoA → phosphatidic acid through sequential acyltransferase reactions. Phosphatidic acid + CTP → CDP-DAG + PPi via CDP-diacylglycerol synthase. CDP-DAG + glycerol-3-phosphate → phosphatidylglycerol phosphate + CMP → dephosphorylation → phosphatidylglycerol (PG). PG + CDP-DAG → cardiolipin + CMP via cardiolipin synthase. CDP-DAG + inositol → phosphatidylinositol + CMP via phosphatidylinositol synthase. Kennedy pathway: phosphatidic acid → DAG via phosphatidic acid phosphatase; choline or ethanolamine + ATP → phosphorylated head group + ADP via kinase; phosphorylated head group + CTP → CDP-choline or CDP-ethanolamine + PPi via cytidylyltransferase; CDP-head group + DAG → PC or PE + CMP via phosphotransferase. Mammalian PS: PC or PE + serine → PS + choline or ethanolamine through Ca²⁺-dependent phosphatidylserine synthases. PS can subsequently undergo decarboxylation to PE.
144. Question: Which phospholipid biosynthesis pathways differ between mammals and yeast, and which phospholipid is converted into phosphorylated signaling lipids? Answer: Yeast can synthesize phosphatidylserine directly from CDP-DAG + serine, whereas mammals primarily form PS by exchanging the head group of PC or PE. Phosphatidylinositol is phosphorylated by phosphatidylinositol kinases to produce phosphoinositide signaling lipids; these kinases do not catalyze PS → PE → PC conversion.
145. Question: Study Guide Question: If malonyl-CoA is synthesized from labeled CO₂, will the final fatty acid contain radioactive carbon? Answer: No. The bicarbonate-derived carboxyl carbon of malonyl-CoA is released as CO₂ during fatty acid synthase condensation and is not retained in the final fatty acid.
146. Question: Why does labeling the CO₂ used by acetyl-CoA carboxylase not result in labeled palmitate? Answer: ACC temporarily adds bicarbonate-derived CO₂ to acetyl-CoA to form malonyl-CoA. Fatty acid synthase removes that additional carboxyl group during condensation, retaining only the two carbons originally supplied by acetyl-CoA.
147. Question: What is the complete fate of radiolabeled bicarbonate-derived carbon during malonyl-CoA formation and fatty acid elongation? Answer: Acetyl-CoA (C2) + H¹⁴CO₃⁻ + ATP → radiolabeled malonyl-CoA (C3) + ADP + Pi via biotin-dependent ACC. The radiolabeled carbon is the newly introduced carboxyl carbon. Acetyl/acyl-KS + malonyl-ACP → β-ketoacyl-ACP + ¹⁴CO₂ via β-ketoacyl-ACP synthase, releasing the label during decarboxylative condensation. The β-keto product is then reduced with NADPH, dehydrated, and reduced again with NADPH to produce a two-carbon-longer acyl chain. The labeled CO₂ is released rather than incorporated into the fatty acid.
148. Question: Which carbons of acetyl-CoA are incorporated into palmitate, and what happens to the carbon added by bicarbonate? Answer: All 16 carbons of palmitate originate from acetyl-CoA-derived two-carbon units. The initial acetyl-CoA primer supplies terminal carbons C15–C16, and seven malonyl-CoA units supply the remaining 14 carbons after losing their bicarbonate-derived carboxyl groups as CO₂.
149. Question: Study Guide Question: Which lipoprotein is primarily responsible for reverse cholesterol transport? Answer: High-density lipoprotein (HDL), which collects cholesterol from peripheral tissues and returns it to the liver.
150. Question: Why is HDL considered protective in cholesterol metabolism? Answer: HDL removes excess cholesterol from extrahepatic tissues and macrophages and delivers it to the liver, where cholesterol can be utilized, converted to bile acids, or eliminated through biliary pathways.
151. Question: What is the complete reverse cholesterol transport pathway, including enzymes and apolipoproteins? Answer: Liver and intestine → nascent HDL containing ApoA-I → ABCA1/ABCG1-mediated cholesterol efflux from peripheral cells → HDL acquires free cholesterol → ApoA-I activates LCAT → phosphatidylcholine (lecithin) + cholesterol → lysophosphatidylcholine + cholesteryl ester. Hydrophobic cholesteryl esters migrate into the HDL core, converting discoidal HDL to mature spherical HDL. HDL returns to the liver → SR-BI mediates selective cholesterol/cholesteryl ester uptake without requiring whole-particle endocytosis. Some HDL cholesteryl esters can also be transferred to ApoB-containing lipoproteins by CETP. Hepatic cholesterol may undergo conversion to bile acids and enter enterohepatic circulation.
152. Question: What are the primary functions of ApoA-I, LCAT, CETP, and SR-BI in reverse cholesterol transport? Answer: ApoA-I activates LCAT and supports HDL cholesterol collection; LCAT esterifies free cholesterol on HDL; CETP transfers cholesteryl esters between lipoproteins; SR-BI mediates selective hepatic uptake of HDL-derived cholesterol.
153. Question: Study Guide Question: Which hormones stimulate fatty acid mobilization from adipose tissue? Answer: Epinephrine (adrenaline), glucagon, and adrenocorticotropic hormone (ACTH) are the hormones listed in the lecture; epinephrine is a major physiological stimulator of human adipocyte lipolysis.
154. Question: Why do epinephrine and other lipolytic hormones stimulate fatty acid mobilization? Answer: They signal increased energy demand and activate cAMP-dependent PKA signaling, allowing stored adipocyte TAGs to be hydrolyzed into fatty acids for oxidation by other tissues.
155. Question: What is the complete hormone-stimulated adipocyte lipolysis pathway? Answer: Epinephrine/glucagon → receptor-mediated Gs activation → adenylyl cyclase → ATP converted to cAMP + PPi → cAMP activates PKA → PKA phosphorylates perilipin and HSL → perilipin releases CGI-58 → CGI-58 activates ATGL → TAG + H₂O → DAG + fatty acid → HSL converts DAG + H₂O → MAG + fatty acid → MGL converts MAG + H₂O → glycerol + fatty acid. Free fatty acids exit adipocytes and bind serum albumin for blood transport. Glycerol travels mainly to the liver, where glycerol kinase uses ATP to form glycerol-3-phosphate, which can enter TAG synthesis or carbohydrate metabolism.
156. Question: How does insulin oppose epinephrine- and glucagon-mediated fatty acid mobilization? Answer: Insulin activates cAMP phosphodiesterase, lowering cAMP and PKA activity, reducing phosphorylation of perilipin and HSL. Consequently, lipolysis decreases and fatty acid storage is favored.
157. Question: Study Guide Question: What is the length of the fatty acyl intermediate after four rounds of fatty acid synthase activity? Answer: 10 carbons (C10; decanoyl-ACP), beginning with a two-carbon acetyl primer and adding two carbons per round.
158. Question: Why does four rounds of fatty acid synthase activity yield a 10-carbon intermediate rather than an 8-carbon intermediate? Answer: Fatty acid synthesis begins with a two-carbon acetyl-CoA primer. Each completed elongation cycle adds two more carbons from malonyl-CoA. Thus, 2 + (4 × 2) = 10 carbons.
159. Question: What are the carbon-chain lengths and chemical reactions across four rounds of fatty acid synthase activity? Answer: Acetyl primer (C2) + malonyl-ACP (C3) → acetoacetyl-ACP (C4) + CO₂ via β-ketoacyl-ACP synthase. Each round consists of condensation/decarboxylation → β-keto reduction (1 NADPH) → dehydration (H₂O released) → enoyl reduction (1 NADPH). Round 1 → butyryl-ACP (C4); round 2 → hexanoyl-ACP (C6); round 3 → octanoyl-ACP (C8); round 4 → decanoyl-ACP (C10). Overall, four elongation rounds consume 4 malonyl-CoA equivalents and 8 NADPH, using one acetyl-CoA primer. Formation of the four malonyl-CoA molecules additionally requires 4 ATP, 4 acetyl-CoA, and 4 HCO₃⁻, with the introduced CO₂ released during condensation.
160. Question: How many fatty acid synthase cycles and NADPH molecules are required to synthesize palmitate from an acetyl primer? Answer: Seven elongation cycles and 14 NADPH molecules produce the 16-carbon palmitate chain from one acetyl-CoA primer and seven malonyl-CoA molecules. The seven malonyl-CoA formation reactions additionally consume seven ATP.
161. Question: Study Guide Question: Which metabolic enzyme is involved in epigenetic regulation of gene expression? Answer: ATP citrate lyase (ACL/ACLY), which produces cytosolic acetyl-CoA used for histone acetylation and regulation of gene transcription.
162. Question: Why does ATP citrate lyase influence gene expression rather than functioning only in lipid biosynthesis? Answer: ATP citrate lyase generates cytosolic and nuclear acetyl-CoA, the acetyl donor used by histone acetyltransferases. Histone lysine acetylation can alter chromatin accessibility and transcriptional activity.
163. Question: How does mitochondrial citrate metabolism produce acetyl-CoA for lipid synthesis and epigenetic regulation? Answer: Mitochondrial acetyl-CoA + oxaloacetate + H₂O → citrate + CoA via citrate synthase. Citrate exits through the mitochondrial citrate transporter. Citrate + CoA + ATP → cytosolic acetyl-CoA + oxaloacetate + ADP + Pi via ATP citrate lyase. Cytosolic acetyl-CoA can be used by ACC → malonyl-CoA → fatty acid synthesis, or by histone acetyltransferases (HATs) to acetylate histone lysine residues. Cytosolic oxaloacetate + NADH + H⁺ → malate + NAD⁺ via malate dehydrogenase; malate + NADP⁺ → pyruvate + CO₂ + NADPH via malic enzyme. Pyruvate returns to mitochondria, where pyruvate carboxylase uses ATP + HCO₃⁻ + biotin to regenerate oxaloacetate.
164. Question: Which metabolic intermediate directly supplies acetyl groups for histone acetylation, and which enzyme produces it from citrate? Answer: Acetyl-CoA supplies acetyl groups to histone acetyltransferases, and ATP citrate lyase produces acetyl-CoA from citrate. The acetyl group is transferred to histone lysine residues, altering chromatin structure and potentially increasing transcription.
165. Question: Study Guide Question: What conditions promote maximal production of malonyl-CoA? Answer: High citrate, abundant ATP, elevated insulin, and dephosphorylated/polymerized acetyl-CoA carboxylase, with low AMP and low long-chain fatty acyl-CoA.
166. Question: Why do high citrate and high insulin levels stimulate malonyl-CoA synthesis? Answer: High citrate signals abundant acetyl-CoA and promotes ACC polymerization into its highly active form; insulin promotes ACC dephosphorylation. Both favor conversion of acetyl-CoA into malonyl-CoA for fatty acid synthesis.
167. Question: What is the complete regulatory mechanism producing maximal malonyl-CoA synthesis? Answer: Fed state → increased glucose uptake and glycolysis → mitochondrial acetyl-CoA accumulation → citrate formation/export → ATP citrate lyase produces cytosolic acetyl-CoA. High citrate allosterically activates ACC and promotes active polymeric assemblies. Insulin activates phosphatases that dephosphorylate ACC, increasing activity. With abundant acetyl-CoA + HCO₃⁻ + ATP + enzyme-bound biotin, ACC catalyzes malonyl-CoA production. Low AMP limits AMPK-mediated ACC inhibition. Low palmitoyl-CoA reduces feedback inhibition. Accumulating malonyl-CoA inhibits CPT-I, reducing mitochondrial fatty acid oxidation.
168. Question: Which factors activate versus inhibit acetyl-CoA carboxylase, and which conditions favor the greatest activity? Answer: Activators: citrate, insulin-mediated dephosphorylation, and active enzyme polymerization. Inhibitors: AMPK-mediated phosphorylation, glucagon/epinephrine signaling, and accumulated long-chain fatty acyl-CoA such as palmitoyl-CoA. Maximal activity is favored by high citrate and dephosphorylated ACC.
169. Question: Study Guide Question: How does insulin regulate acetyl-CoA carboxylase? Answer: Insulin activates ACC by promoting its dephosphorylation through a phosphatase, increasing malonyl-CoA production and fatty acid synthesis.
170. Question: Why does insulin activate acetyl-CoA carboxylase after a carbohydrate-rich meal? Answer: Insulin signals abundant energy and promotes anabolic lipid storage. Dephosphorylated ACC is more active and converts cytosolic acetyl-CoA into malonyl-CoA, the committed precursor for fatty acid synthesis.
171. Question: What is the complete insulin-dependent mechanism regulating ACC and fatty acid metabolism? Answer: High blood glucose → pancreatic β-cells release insulin → insulin receptor signaling → increased ACC-directed phosphatase activity → ACC dephosphorylation and activation. Citrate further promotes formation of active ACC polymers. Acetyl-CoA + HCO₃⁻ + ATP → malonyl-CoA + ADP + Pi through biotin-dependent ACC. Malonyl-CoA → fatty acid synthase-mediated elongation using NADPH → palmitate synthesis. Simultaneously, malonyl-CoA inhibits CPT-I, suppressing fatty acid β-oxidation. Insulin also activates phosphodiesterase → cAMP → AMP, reducing PKA-dependent lipolysis.
172. Question: How do insulin, glucagon, epinephrine, and AMPK differ in regulating acetyl-CoA carboxylase? Answer: Insulin promotes ACC dephosphorylation and activation; glucagon and epinephrine favor ACC inhibition and fatty acid mobilization; AMPK is the main energy-sensing kinase that phosphorylates and inhibits ACC when cellular AMP is elevated.
173. Question: Study Guide Question: Does insulin inhibit lipolysis by increasing or decreasing cAMP levels in adipocytes? Answer: Decreasing cAMP levels, primarily through activation of cAMP phosphodiesterase, which reduces PKA-dependent lipase activation.
174. Question: Why does lowering cAMP inhibit TAG breakdown in adipocytes? Answer: cAMP activates PKA, which phosphorylates perilipin and HSL to promote lipid mobilization. Insulin lowers cAMP, thereby decreasing PKA activity and suppressing activation of the lipolytic machinery.
175. Question: What is the complete insulin-mediated mechanism for suppressing lipolysis in adipocytes? Answer: Insulin → insulin receptor tyrosine kinase activation → IRS/PI3K signaling → Akt activation → activation of phosphodiesterase 3B (PDE3B) → cAMP + H₂O → AMP → decreased cAMP-dependent PKA activity. Reduced PKA signaling decreases phosphorylation of perilipin and HSL → CGI-58 remains more strongly restrained by perilipin → decreased ATGL activation → reduced TAG → DAG → MAG → glycerol + fatty acid hydrolysis. Overall, fatty acid mobilization decreases and TAG storage is favored.
176. Question: Which second messenger increases adipocyte lipolysis, and which enzyme is primarily responsible for insulin-induced reduction of that messenger? Answer: cAMP increases lipolysis through PKA activation; phosphodiesterase, especially PDE3B, degrades cAMP to AMP under insulin signaling. Adenylyl cyclase produces cAMP from ATP during lipolytic hormone stimulation.
177. Question: Study Guide Question: What substrates and cofactors are required for the synthesis of malonyl-CoA? Answer: Acetyl-CoA, bicarbonate (HCO₃⁻), ATP, and biotin, with the reaction catalyzed by acetyl-CoA carboxylase.
178. Question: What are the distinct roles of acetyl-CoA, bicarbonate, ATP, and biotin in malonyl-CoA synthesis? Answer: Acetyl-CoA supplies the two-carbon substrate; bicarbonate supplies the additional carboxyl group; ATP provides activation energy; biotin temporarily carries the activated CO₂ to acetyl-CoA.
179. Question: What is the complete mechanism and stoichiometry of malonyl-CoA synthesis? Answer: 1. Biotin carboxylation: HCO₃⁻ + ATP + enzyme-bound biotin → carboxybiotin + ADP + Pi, catalyzed by the biotin carboxylase domain of ACC. 2. Carboxyl transfer: the biotin carrier domain moves carboxybiotin to the transcarboxylase active site. 3. Malonyl-CoA formation: carboxybiotin + acetyl-CoA → malonyl-CoA + regenerated biotin, catalyzed by the carboxyltransferase domain. Overall: acetyl-CoA + HCO₃⁻ + ATP → malonyl-CoA + ADP + Pi. ACC contains covalently attached biotin bound to lysine, and the reaction occurs primarily in the cytosol during fatty acid synthesis.
180. Question: Does the synthesis of malonyl-CoA require NADPH, and how does this differ from subsequent fatty acid elongation? Answer: No. ACC requires ATP and biotin but not NADPH. Fatty acid synthase subsequently consumes two NADPH molecules per elongation cycle, one for β-keto reduction and one for enoyl reduction.
181. Question: Study Guide Question: Is malonyl-CoA used for cholesterol synthesis? Answer: No. Cholesterol is synthesized from acetyl-CoA through HMG-CoA, mevalonate, activated isoprenes, and squalene, without malonyl-CoA.
182. Question: Why does fatty acid synthesis require malonyl-CoA whereas cholesterol biosynthesis does not? Answer: Fatty acid synthesis uses decarboxylative condensation of malonyl groups to extend acyl chains by two carbons. Cholesterol synthesis instead converts acetyl-CoA into five-carbon activated isoprene units through the mevalonate pathway.
183. Question: How do the pathways of fatty acid synthesis and cholesterol synthesis diverge from acetyl-CoA? Answer: Fatty acid synthesis: acetyl-CoA + HCO₃⁻ + ATP → malonyl-CoA via biotin-dependent ACC → malonyl-ACP loading → repeated condensation, reduction (NADPH), dehydration, and reduction (NADPH) via FAS → palmitate. Cholesterol synthesis: 2 acetyl-CoA → acetoacetyl-CoA via thiolase → HMG-CoA via HMG-CoA synthase with another acetyl-CoA → mevalonate via HMG-CoA reductase using 2 NADPH → IPP and DMAPP using 3 ATP per mevalonate → geranyl-PP → farnesyl-PP → squalene → lanosterol → cholesterol. Malonyl-CoA is not an intermediate in the cholesterol pathway.
184. Question: Which enzymes catalyze the committed steps of fatty acid synthesis and cholesterol synthesis, and which precursor distinguishes the pathways? Answer: ACC catalyzes the committed step of fatty acid synthesis by producing malonyl-CoA; HMG-CoA reductase catalyzes the committed, rate-limiting step of cholesterol synthesis by producing mevalonate. Both use acetyl-CoA-derived carbon, but only fatty acid synthesis uses malonyl-CoA.
185. Question: Study Guide Question: What is the correct order of lipoprotein transformation from dietary to circulatory forms? Answer: Dietary pathway: chylomicrons → chylomicron remnants → liver. Endogenous pathway: VLDL → IDL → LDL. These are two distinct pathways, not one continuous sequence.
186. Question: Why do chylomicrons and VLDL follow different transformation pathways? Answer: Chylomicrons originate from dietary lipids in the intestine and deliver their remnants to the liver. VLDL originates from the liver and progressively loses TAGs to form IDL and LDL in circulation.
187. Question: What are the complete exogenous, endogenous, and reverse cholesterol transport pathways? Answer: Exogenous: dietary TAGs/cholesterol → small-intestinal digestion and absorption → enterocyte TAG re-esterification → chylomicron assembly with ApoB-48 → lymph → blood → acquisition of ApoC-II and ApoE → ApoC-II activates LPL → TAG hydrolysis → chylomicron remnants → hepatic ApoE-dependent uptake. Endogenous: hepatic TAG/cholesterol → VLDL with ApoB-100 → blood → LPL removes TAGs → IDL → further lipolysis by hepatic and other lipases → LDL → ApoB-100-mediated LDL receptor uptake by liver and peripheral tissues. Reverse transport: nascent HDL with ApoA-I → cholesterol collection from peripheral tissues → LCAT esterifies cholesterol → mature HDL → hepatic SR-BI selectively takes up cholesterol → bile acid synthesis, storage, or other hepatic metabolism.
188. Question: Which lipoprotein transformations occur through TAG removal, and which involve direct hepatic remnant uptake? Answer: VLDL → IDL → LDL occurs through progressive TAG removal. Chylomicron → chylomicron remnant occurs through TAG removal, followed by hepatic uptake of the remnant through ApoE-dependent recognition. Chylomicron remnants do not ordinarily transform into LDL.
189. Question: Study Guide Question: How does the cell regulate cholesterol levels through transcription, degradation, and enzyme activity? Answer: Through SREBP-dependent transcription, sterol-triggered HMG-CoA reductase degradation, AMPK/insulin-dependent phosphorylation, ACAT-mediated cholesterol esterification, and regulation of LDL receptor expression.
190. Question: How do high versus low intracellular cholesterol levels affect SREBP and HMG-CoA reductase? Answer: Low cholesterol activates SREBP processing and increases transcription of HMG-CoA reductase and LDLR. High cholesterol retains SREBP in the ER, promotes HMG-CoA reductase degradation, reduces LDLR expression, and increases cholesterol esterification by ACAT.
191. Question: What is the complete cholesterol homeostasis mechanism involving SREBP, SCAP, Insig, HMG-CoA reductase, AMPK, and ACAT? Answer: Low cholesterol: ER sterol levels decrease → SCAP dissociates from Insig → SCAP transports SREBP in COPII-coated vesicles to the Golgi → site-1 protease (S1P) and site-2 protease (S2P) cleave SREBP → active SREBP enters nucleus → binds sterol regulatory elements → increases HMG-CoA reductase, LDLR, and other lipid synthesis genes. High cholesterol: cholesterol promotes association of SCAP with Insig → SREBP remains in ER → reduced transcription of cholesterol synthesis and uptake genes. Insig-mediated sterol sensing also stimulates ubiquitination and proteasomal degradation of ER HMG-CoA reductase. High cholesterol activates ACAT, converting cholesterol + fatty acyl-CoA → cholesteryl ester + CoA for storage. Low cellular ATP/high AMP: AMPK phosphorylates and inhibits HMG-CoA reductase; insulin-mediated dephosphorylation activates it.
192. Question: Which cholesterol-regulatory responses are expected when intracellular cholesterol or AMP increases? Answer: High cholesterol → decreased SREBP activation, decreased HMG-CoA reductase transcription, increased reductase degradation, decreased LDLR expression, and increased ACAT-mediated esterification. High AMP → AMPK activation → HMG-CoA reductase phosphorylation and inhibition.
193. Question: Study Guide Question: What determines whether the LDL receptor is recycled or degraded after internalization? Answer: Normal dissociation of LDL from its receptor in the acidic endosome allows LDLR recycling. Failure of proper dissociation or sorting can promote receptor degradation instead.
194. Question: Why are LDL receptors normally recycled after receptor-mediated endocytosis? Answer: LDL and LDLR are sorted into different endosomal pathways. Acidification promotes dissociation of the LDL particle, allowing LDLR to return to the plasma membrane for additional rounds of uptake, while LDL cargo is delivered to lysosomes for degradation.
195. Question: What is the mechanism of LDL uptake and endosomal sorting that permits LDL receptor recycling? Answer: LDL containing ApoB-100 binds plasma membrane LDLR → clathrin-coated pit formation → clathrin-mediated endocytosis → endosome formation → V-type H⁺-ATPase uses ATP to pump H⁺ into the endosome → decreasing pH promotes conformational changes and dissociation of LDL from LDLR → LDLR-containing membrane regions bud off into recycling carriers → LDLR returns to the plasma membrane. LDL remains in the endosomal pathway → lysosomal fusion and acidification → lysosomal acid lipase hydrolyzes cholesteryl esters into cholesterol and fatty acids, while proteases degrade ApoB-100. The supplied Lehninger chapter specifically depicts recycling of LDLR and degradation of LDL cargo.
196. Question: In normal LDL receptor-mediated endocytosis, which component is recycled and which is degraded, and what distinction is most likely to be tested? Answer: The LDL receptor is normally recycled to the plasma membrane, while the internalized LDL particle is degraded in lysosomes. Failure of receptor recycling can impair LDL clearance. The supplied lecture and textbook emphasize this normal sorting pathway rather than specifying an additional receptor-degradation signal.
197. Question: Study Guide Question: Which LDL receptor mutations lead to the most severe and early-onset hypercholesterolemia? Answer: Biallelic (homozygous or compound heterozygous) severe loss-of-function LDLR mutations, especially those abolishing receptor production or LDL binding, cause the most severe early-onset familial hypercholesterolemia.
198. Question: Why are individuals with two defective LDLR alleles generally more severely affected than individuals with one defective allele? Answer: Two severely impaired LDLR alleles greatly reduce or eliminate LDL receptor function, preventing efficient LDL clearance from blood. A single functional allele usually retains partial receptor activity, producing a less severe phenotype.
199. Question: What is the cellular mechanism connecting LDL receptor mutations to familial hypercholesterolemia and atherosclerosis? Answer: Normal pathway: LDL containing ApoB-100 → LDLR binding → receptor-mediated endocytosis → lysosomal release of cholesterol → intracellular cholesterol feedback inhibits new cholesterol synthesis. Defective LDLR pathway: mutations impair receptor production, LDL binding, endocytosis, or receptor recycling → decreased hepatic LDL clearance → elevated circulating LDL → LDL accumulation and oxidation in arterial walls → macrophage uptake of oxidized LDL → cholesteryl ester accumulation → foam-cell formation → atherosclerotic plaques. Insufficient intracellular LDL-derived cholesterol can also fail to suppress SREBP-dependent cholesterol synthesis.
200. Question: Which LDL receptor abnormalities produce the most severe familial hypercholesterolemia, and how does this differ from Niemann-Pick type C disease? Answer: Biallelic receptor-negative or severely LDL-binding-defective LDLR mutations cause especially severe familial hypercholesterolemia. In Niemann-Pick type C, LDL uptake can occur, but defective NPC1/NPC2-mediated cholesterol transport causes cholesterol accumulation within lysosomes rather than defective initial LDL receptor binding.
201. Question: Study Guide Question: What proportion of fatty acids released during starvation are re-esterified into TAGs? Answer: Approximately 75% of fatty acids released during TAG breakdown are re-esterified into TAGs, even during starvation.
202. Question: Why does substantial fatty acid re-esterification continue during fasting or starvation? Answer: The triacylglycerol cycle continuously hydrolyzes and resynthesizes TAGs, regulating the supply of circulating free fatty acids. Glyceroneogenesis provides glycerol-3-phosphate needed for re-esterification when glucose availability is limited.
203. Question: What is the complete triacylglycerol cycle and glyceroneogenesis pathway during starvation? Answer: Adipose TAG → DAG + fatty acid (ATGL) → MAG + fatty acid (HSL) → glycerol + fatty acid (MGL). Some released fatty acids are immediately re-esterified within adipocytes; others bind albumin → travel to liver → become fatty acyl-CoA → undergo TAG resynthesis → are exported as VLDL → ApoC-II-activated LPL releases fatty acids in peripheral capillaries → adipose tissue takes them up for re-esterification. Glyceroneogenesis: pyruvate + HCO₃⁻ + ATP → oxaloacetate + ADP + Pi via biotin-dependent pyruvate carboxylase → oxaloacetate + GTP → PEP + GDP + CO₂ via PEP carboxykinase (PEPCK) → reverse glycolytic reactions produce triose phosphates → DHAP → DHAP + NADH + H⁺ → glycerol-3-phosphate + NAD⁺ via glycerol-3-phosphate dehydrogenase. Glycerol-3-phosphate + fatty acyl-CoAs → phosphatidic acid → DAG → TAG, permitting approximately 75% fatty acid recycling.
204. Question: Which enzyme controls glyceroneogenesis during fasting, and why is this pathway especially important in adipose tissue? Answer: PEP carboxykinase (PEPCK) is a major regulatory enzyme controlling glyceroneogenesis. Adipocytes have low glycerol kinase activity, so they rely heavily on DHAP-derived glycerol-3-phosphate to re-esterify fatty acids during fasting.
205. Question: Study Guide Question: What is catabasis and how does it relate to inflammation resolution? Answer: Catabasis is the active resolution of inflammation and restoration of tissue homeostasis, promoted by specialized pro-resolving mediators such as lipoxins, resolvins, protectins, and maresins.
206. Question: Why is catabasis considered an active biochemical process rather than simply the disappearance of inflammation? Answer: Catabasis requires specialized signaling molecules that terminate excessive leukocyte recruitment, promote clearance of inflammatory debris and dead cells, and support tissue repair. Resolution restores homeostasis rather than merely suppressing inflammatory symptoms.
207. Question: What is the biochemical pathway linking polyunsaturated fatty acids, eicosanoids, and specialized pro-resolving mediators to catabasis? Answer: Membrane phospholipids containing polyunsaturated fatty acids → activation of Ca²⁺-dependent phospholipase A₂ → release of arachidonic acid (ω-6) or other polyunsaturated fatty acid precursors. Arachidonic acid can enter the COX pathway → PGG₂ → PGH₂ → prostaglandins and thromboxanes, or the lipoxygenase pathway → leukotrienes and lipoxins. Early inflammatory mediators support vascular responses and leukocyte recruitment. During resolution, lipid mediator production shifts toward specialized pro-resolving mediators (SPMs): arachidonic acid-derived lipoxins and EPA/DHA-derived resolvins, protectins, and maresins, formed through lipoxygenase and related oxygenation pathways. These mediators reduce neutrophil infiltration, stimulate macrophage-mediated clearance of apoptotic cells (efferocytosis), promote debris removal, and support restoration of normal tissue structure and function.
208. Question: Which lipid mediators are most directly associated with initiating inflammation versus promoting catabasis? Answer: Many ω-6-derived prostaglandins, thromboxanes, and leukotrienes promote inflammation; specialized pro-resolving mediators such as lipoxins, resolvins, protectins, and maresins promote its resolution. However, individual prostaglandins and leukotrienes can also participate in resolution, so the classification is not absolute.
209. Question: Study Guide Question: What is phosphopantetheine? Answer: 4′-Phosphopantetheine is a vitamin B5-derived prosthetic group attached to acyl carrier protein (ACP), providing a flexible sulfhydryl-bearing arm that carries fatty acyl intermediates during synthesis.
210. Question: Why is phosphopantetheine essential for fatty acid synthase activity? Answer: Its terminal sulfhydryl group forms thioester bonds with growing fatty acyl chains, while its flexible arm transports those intermediates between catalytic domains of fatty acid synthase.
211. Question: How does 4′-phosphopantetheine participate in the fatty acid synthase reaction cycle? Answer: Pantothenic acid (vitamin B5) → component of coenzyme A and 4′-phosphopantetheine → phosphopantetheine is covalently attached to a conserved serine residue of ACP through a phosphodiester bond. The prosthetic group's terminal −SH forms a thioester with an acetyl, malonyl, or growing fatty acyl group. Acetyl-CoA or malonyl-CoA → ACP-bound acyl groups through the malonyl/acetyltransferase domain (MAT). The growing acyl group is transferred between the ACP phosphopantetheine −SH and the β-ketoacyl synthase cysteine −SH during repeated reactions: condensation with loss of CO₂ → β-keto reduction using NADPH → dehydration releasing H₂O → enoyl reduction using NADPH → fatty acyl-ACP elongated by two carbons. The flexible phosphopantetheine arm transports intermediates between active sites, and thioesterase eventually hydrolyzes palmitoyl-ACP to release palmitate.
212. Question: How does phosphopantetheine differ from biotin, and which molecules carry acyl groups during fatty acid synthesis versus breakdown? Answer: Phosphopantetheine carries fatty acyl groups through thioester bonds, whereas biotin carries activated CO₂ during carboxylation. Fatty acid synthesis uses ACP-bound phosphopantetheine to carry intermediates; β-oxidation uses coenzyme A, which also contains a phosphopantetheine-derived sulfhydryl group.
213. Question: Study Guide Question: Are both chylomicrons and LDL particles taken up by the liver via the LDL receptor? Answer: No. LDL binds LDLR through ApoB-100, while intact chylomicrons are first converted into remnants that undergo ApoE-mediated hepatic uptake through remnant-recognizing receptors.
214. Question: Why do LDL and chylomicron remnants use different apolipoproteins for hepatic recognition? Answer: LDL contains ApoB-100, whose receptor-binding domain is recognized by LDLR. Chylomicrons contain ApoB-48, which lacks that domain, so remnant clearance depends primarily on ApoE.
215. Question: What are the distinct hepatic uptake mechanisms for LDL and chylomicron remnants? Answer: LDL pathway: VLDL → IDL → LDL containing ApoB-100 → ApoB-100 binds hepatic LDLR → clathrin-mediated endocytosis → acidic endosomal dissociation → LDLR recycling → lysosomal degradation of LDL and release of free cholesterol. Chylomicron pathway: intestinal chylomicron containing ApoB-48 → acquisition of ApoC-II and ApoE from HDL → ApoC-II activates LPL → TAG hydrolysis → chylomicron remnant enriched in cholesterol and ApoE → ApoE binds hepatic remnant-recognizing receptors, including LDL receptor-related protein and potentially LDLR → endocytosis → lysosomal degradation and release of lipids.
216. Question: Can the LDL receptor recognize ApoE even though ApoB-100 is the primary ligand associated with LDL uptake? Answer: Yes. ApoE can interact with LDLR as well as other hepatic remnant receptors. The main distinction is that LDL uses ApoB-100 for LDLR recognition, whereas chylomicron remnants rely on ApoE because ApoB-48 cannot bind LDLR through the ApoB-100 recognition domain.
217. Question: Study Guide Question: What is the rate-limiting enzyme in cholesterol biosynthesis? Answer: HMG-CoA reductase (3-hydroxy-3-methylglutaryl-CoA reductase), which catalyzes the NADPH-dependent conversion of HMG-CoA into mevalonate.
218. Question: Why is HMG-CoA reductase the major regulatory enzyme of cholesterol biosynthesis? Answer: HMG-CoA reductase catalyzes the committed, rate-limiting step of the mevalonate pathway. Its activity and abundance are tightly controlled by cellular cholesterol levels, AMP/ATP status, hormonal signaling, and sterol-dependent protein degradation.
219. Question: What is the complete HMG-CoA reductase reaction and its regulatory mechanisms? Answer: 2 acetyl-CoA → acetoacetyl-CoA + CoA via thiolase; acetoacetyl-CoA + acetyl-CoA + H₂O → HMG-CoA + CoA via cytosolic HMG-CoA synthase. HMG-CoA + 2 NADPH + 2H⁺ → mevalonate + CoA + 2 NADP⁺ via HMG-CoA reductase, an ER membrane-associated enzyme whose catalytic domain faces the cytosol. Regulation: high AMP/low ATP → AMPK phosphorylates and inhibits HMG-CoA reductase; insulin promotes phosphatase-dependent dephosphorylation and activation; glucagon favors inhibition. High cholesterol → Insig-dependent ubiquitination and proteasomal degradation of reductase + ER retention of SREBP-SCAP → decreased reductase transcription. Low cholesterol → SCAP transports SREBP to Golgi → S1P/S2P cleavage → nuclear SREBP increases reductase expression. Statins competitively inhibit HMG-CoA reductase, reducing mevalonate and downstream cholesterol synthesis.
220. Question: How do HMG-CoA reductase, HMG-CoA synthase, and HMG-CoA lyase differ, and which enzyme is targeted by statins? Answer: HMG-CoA synthase forms HMG-CoA; HMG-CoA lyase cleaves mitochondrial HMG-CoA into acetoacetate during ketogenesis; HMG-CoA reductase converts HMG-CoA into mevalonate during cholesterol synthesis. Statins are competitive inhibitors of HMG-CoA reductase, the rate-limiting cholesterol biosynthesis enzyme.